Relief from symptoms caused by over **150** indoor & outdoor allergens*

*Airborne allergens such as pets, dust, pollen and mould.

Clarityn Allergy 10mg Tablets (loratadine) are indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. Dosage and Administration: Adults, elderly and children aged 6 years and over – Bodyweight over 30kg: One tablet once daily. Children younger than 6 years or bodyweight 30kg or less: Not recommended. Contraindications: Hypersensitivity to the active substances or to any other ingredients. Warnings and Precautions: In severe liver impairment, patients should be given a lower initial dose as they may have reduced loratadine clearance: an initial dose of 10 mg every other day is recommended for adults and children weighing more than 30kg. Clarityn should be discontinued at least 48 hours before skin tests. Contains lactose; thus, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Side-effects: Very rarely hypersensitivity reactions (including angioedema and anaphylaxis), dizziness, convulsion, tachycardia, palpitation, nausea, dry mouth, gastritis, abnormal hepatic function, rash, alopecia and fatigue. Weight increase was also reported. In children (2 to 12 years of age), headache, nervousness and fatigue were most common. In adults and adolescents, somnolence, headache, increased appetite and insomnia were reported most frequently. Use in pregnancy and breast-feeding: Preferable to avoid during pregnancy. Clarityn should not be used during breast-feeding. RRP (Excl. VAT): 7's £3.59; 14's £5.35; 30's £8.23. MA Number: PL 00010/0657. MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD. Legal Category: GSL. Date of Preparation: March 2022

Clarityn® Allergy 1mg/ml Syrup (loratadine) is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. Dosage and Administration: Adults and children over 12 years of age: 10ml (10mg) of syrup once daily. Children 2 to 12 years of age – Bodyweight more than 30kg: 10ml (10mg) of the syrup once daily. Bodyweight 30kg or less: 5ml (5mg) of the syrup once daily. Contraindications: Hypersensitivity to the active substances or to any other ingredients. Warnings and Precautions: Should be administered with caution in patients with severe liver impairment. Clarityn should be discontinued at least 48 hours before skin tests. Contains maltitol and sorbitol; thus patients with rare hereditary problems of fructose intolerance should not take this medicine. Side-effects: Hypersensitivity reactions (including angioedema and anaphylaxis), dizziness, convulsion, tachycardia, palpitation, nausea, dry mouth, gastritis, abnormal hepatic function, rash, alopecia and fatigue listed as very rare (< 1/10,000). In adults and adolescents, somnolence, headache, increased appetite and insomnia were reported most frequently. Weight increase was also reported. In children (2 to 12 years of age), headache, nervousness and fatigue are listed as common (≥ 1/100 to < 1/10). Use in pregnancy and breast-feeding: Preferable to avoid during pregnancy. Not recommended during breast-feeding. RRP (Excl. VAT): 60ml £4.31. MA Number: PL 00010/0656. MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD. Legal Category: GSL. Date of Preparation: March 2022.

Clarinaze® Allergy Control 0.05% nasal spray (0.05% mometasone furoate). Indications: Symptomatic treatment of seasonal or perennial allergic rhinitis in Adults aged ≥18 years. Dosage and Administration: Two actuations (50mcg/actuation) in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, dose reduction to one actuation in each nostril (total dose 100 mcg). Product requires initial priming prior to first use. Contraindications: Hypersensitivity to any of the ingredients, presence of untreated localised infection of the nasal mucosa (e.g. herpes simplex), recent nasal surgery or trauma where healing has not yet occurred. Warnings and Precautions: Treatment should be stopped and medical advice sought if no improvement is seen in 14 days and if symptoms have improved but are not adequately controlled. Do not use for >3 months without consulting a doctor. Use with caution in patients with: active or quiescent tuberculosis, untreated fungal, bacterial, or systemic viral infections. Potentially immunosuppressed patients receiving corticosteroids should be warned of risk of infections (e.g., chickenpox, measles) and of the importance of obtaining medical advice if such exposure occurs. Patients on treatment over several months should be examined periodically for changes in nasal mucosa. Product contains benzalkonium chloride which may cause irritation or swelling inside the nose. Treatment is not recommended in patients with nasal septum perforation. Systemic effects of nasal corticosteroids may occur. Instances of increased intraocular pressure have been reported. Patients transferred from long-term administration of systemically active corticosteroids require careful attention. Treatment with higher than recommended doses may result in clinically significant adrenal suppression. Side Effects: Epistaxis, Pharyngitis, Upper respiratory tract infection, Headache, Nasal burning, Nasal irritation, Nasal ulceration, Throat irritation. Pregnancy: No or limited data are available, treatment not recommended unless potential benefit to mother justifies potential risk. RRP (Excl. VAT): £11.91– 140 actuations. MA Number: PL 00010/0663 MA Holder: Bayer plc, 400 South Oak Way, Reading, RG2 6AD, UK. Legal Category: P. Date of Preparation:March 2022.

® Registered trademark of Bayer